VLA15, Valneva's vaccine candidate for Lyme disease, is being prepared in collaboration with Pfizer ( PFE - Free Report ). Both Valneva and Pfizer successfully completed phase II studies, evaluating VLA15 in both adults (aged 18 years and above) and pediatric participants (from 5 years to 17 years). Based on data from these phase II studies, both Pfizer and Valneva plan to proceed with a phase III study of the vaccine in both pediatric and adult participants, which is expected to start in third-quarter 2022.